Anika Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $32,610 | $29,612 | $30,615 | $27,817 |
Gross Profit | 21,244 | 18,997 | 19,179 | 15,584 |
EBITDA | 4,885 | -3,414 | 2,082 | -836 |
EBIT | 3,380 | -4,821 | 764 | -2,236 |
Net Income | 3,309 | -5,056 | 292 | -2,329 |
Net Change In Cash | 32,610 | 29,612 | 30,615 | 27,817 |
Free Cash Flow | -2,133 | -6,277 | 3,989 | 4,983 |
Cash | 38,412 | 41,020 | 57,481 | 57,990 |
Basic Shares | 13,430 | 13,531 | 14,669 | 14,419 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $112,819 | $119,907 | $120,792 | $156,236 |
Gross Profit | 63,807 | 75,998 | 82,532 | 93,576 |
EBITDA | -3,578 | 5,357 | 17,373 | -4,913 |
EBIT | -9,307 | -2,764 | 3,156 | -19,400 |
Net Income | -10,880 | -56,385 | -82,667 | -14,859 |
Net Change In Cash | 112,819 | 119,907 | 120,792 | 156,236 |
Cost of Revenue | -7,929 | |||
Free Cash Flow | 4,362 | -2,331 | -7,215 | -3,077 |
Cash | 57,481 | 55,629 | 68,740 | 86,327 |
Basic Shares | 14,339 | 14,721 | 14,656 | 14,561 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | $0.30 |
2026-03-31 | $0.27 |
2025-12-31 | $0.13 |
2025-09-30 | -$0.17 |